JPRN-UMIN000035889已完成未知
ivOlumaB and chemoradiotherapy for EsophageaL cancer - NivOlumaB and chemoradiotherapy for EsophageaL cancer
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 20years-old 至 75years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1. Synchronous or metachronous (within 5 years) malignancy except cancer with 5-year relative survival rate of 95% or more such as carcinoma in situ, intramucosal tumor, or early stage cancers. 2. Current or past history of severe hypersensitivity to any other antibody products. 3. Active autoimmune disease. 4. Intestinal lung disease or pulmonary fibrosis 5. Diverticulitis or peptic ulcer 6. Pleural effusion or ascites necessary for emission 7. Uncontrollable tumor pain 8. Transient ischemic attack, cerebrovascular accident, thrombosis or thromboembolism within 180 days 9. Uncontrollable severe cardiovascular disease 10. Cannot biopsy using the esophagogastoroduodenoscope due to anticoagulant therapy 11. Patients requiring systemic steroid medication or the other immunosuppressive drug excluding corticosteroid drugs before 14 days. 12. Uncontrollable diabetes 13. Treating systemic infection 14. Patients received live vaccines 15. HBs antigen positive or HCV antibody positive 16. Either HBs antibody positive or HBc antibody positive and HBV-DNA detection although HBs antigen is negative 17. Females who are or may be pregnant or lactating 18. Administration of unapproved drugs within 28 days 19. Patients who are incapable of gibing consent (for example, dementia) 20. Any other inadequacy for this study
研究者
相似试验
已完成
1 期
ivolumab and chemoradiotherapy for esophageal cancerJPRN-jRCT1091220408Manabu Muto60
已完成
2 期
eoadjuvant chemoradiotherapy followed by esophagectomy for REG I positive T4, N4 or many thoracic esophageal cancerthoracic esophageal cancerJPRN-UMIN000001626The Cancer Board of Esophageal Cancer in Akita University Hospital30
进行中（未招募）
1 期
Eoadjuvant chemoradiotherapy for Esophageal squamous cell carcinoma versus Definitive chemoradiotherapy with salvage Surgery as needed (The NEEDS Trial)Resectable locally advanced squamous cell carcinoma (SCC) of the esophagusCTIS2022-500966-82-00Karolinska University Hospital1,010
进行中（未招募）
1 期
Combined chemotherapy and radiotherapy followed by planned surgery compared to combined chemotherapy and radiotherapy with surgery only when really needed, for patients with cancer in the esophagus.Resectable locally advanced squamous cell carcinoma (SCC) of the esophagusMedDRA version: 21.1Level: LLTClassification code 10025899Term: Malignant neoplasm of esophagusSystem Organ Class: 100000004864MedDRA version: 21.1Level: LLTClassification code 10025901Term: Malignant neoplasm of esophagus, unspecifiedSystem Organ Class: 100000004864EUCTR2020-000149-15-IEKarolinska University Hospital1,020
进行中（未招募）
1 期
Combined chemotherapy and radiotherapy followed by planned surgery compared to combined chemotherapy and radiotherapy with surgery only when really needed, for patients with cancer in the esophagus.Resectable locally advanced squamous cell carcinoma (SCC) of the esophagusMedDRA version: 21.1Level: LLTClassification code 10025899Term: Malignant neoplasm of esophagusSystem Organ Class: 100000004864MedDRA version: 21.1Level: LLTClassification code 10025901Term: Malignant neoplasm of esophagus, unspecifiedSystem Organ Class: 100000004864EUCTR2020-000149-15-SEKarolinska University Hospital1,020